Strides Pharma Science Limited (Strides) today announced that it has secured the approval of its equity shareholders and secured creditors with overwhelming majority , along with those of OneSource Specialty Pharma Limited and SteriScience Specialties Private Limited, in meetings convened under the guidance of the
Allergan Aesthetics, an AbbVie company, underscored India’s rapid emergence as a key player in the global aesthetic medicine landscape at its sensitization conclave, ‘Aesthetics- Empowering Confidence’. The event brought together leading Aesthetic practitioners like Dr. Sanjeev Nelogi, Dr. Rashmi Shetty, and Dr. Anjali Ghatge, to
Eris Lifesciences Ltd., a leading Indian branded formulations company, today announced the expansion of its Sterile Injectables footprint through the acquisition of 51% equity stake in Swiss Parenterals Ltd. for a consideration of INR 637.50 crore. This deal also marks the entry of Eris into
The company expects this approval for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities in Baddi to pave the way for GMP certifications from European Medicines Agency and other Pharmaceutical Inspection
Semaglutide, a GLP-1 receptor analogue (GLP-1 RA), indicated for the management of type 2 diabetes has been developed in an oral formulation for the first time. Oral semaglutide will be a gamechanger for people with type 2 diabetes who prefer oral medications over injections. was
